4 not yet recruiting, 3 completed, 2 active not recruiting, 2 recruiting. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Not yet recruiting 4, Completed 3, Active not recruiting 2, Recruiting 2 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow CLL (Chronic Lymphocytic Leukemia): new trials by email Literature Review of CLL (Chronic Lymphocytic Leukemia) trials Research Report on CLL (Chronic Lymphocytic Leukemia)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL Zanubrutinib, Sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | German CLL Study Group | 80 | 2026-12-01 | 2026-10-27 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). Pirtobrutinib, Fludarabine, Cyclophosphamide - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 82 | 2026-09-01 | 2026-06-03 |
| A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL MS-553, DS1, MS-553, DS2 - CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma) | Phase 1 / Phase 2 | Not yet recruiting | MingSight Pharmaceuticals, Inc | 12 | 2026-07-01 | 2025-09-29 |
| A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients Zanubrutinib and sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2026-06-01 | 2026-06-26 |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C - AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Recruiting | Center for International Blood and Marrow Transplant Research | 358 | 2025-07-25 | 2026-03-17 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Improving Blood Stem Cell Collection and Transplant Procedures Stem Cell Transplantation - Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 43 | 2012-01-13 | 2018-07-05 |
| PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PCI 32765 - Leukemia, Leukemia, Lymphocytyc | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 86 | 2012-01-05 | 2026-04-28 |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL Fludarabine Phosphate, Ofatumumab, Cyclophosphamide - Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2010-07-01 | 2023-11-28 |
| Stem Cell Transplantation for Patients With Cancers of the Blood Miltenyi system - CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 61 | 2007-04-01 | 2018-07-13 |
Leukemia, B-Cell (11) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Anemia, Refractory, with Excess of Blasts (3) · Leukemia, Myeloid, Acute (3) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, T-Cell, Cutaneous (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Hematologic Diseases (10) · Leukemia, Lymphoid (10) · Chronic Disease (8) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Leukemia (7) · Bone Marrow Diseases (4)
Cyclophosphamide (3) · Stem Cell Transplantation (2) · fludarabine phosphate (2) · zanubrutinib (2) · Bone Marrow Transplantation (1) · Filgrastim (1) · Melphalan (1) · Mesna (1) · Mycophenolic Acid (1) · fludarabine (1) · ibrutinib (1) · obinutuzumab (1) · ofatumumab (1) · pirtobrutinib (1)
National Heart, Lung, and Blood Institute (NHLBI) (4) · Center for International Blood and Marrow Transplant Research (1) · French Innovative Leukemia Organisation (1) · German CLL Study Group (1) · MingSight Pharmaceuticals, Inc (1) · Ossium Health, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of California, Irvine (1)
United States (7) · China (1)
Minocher M Battiwalla, M.D. (2) · Andy Itsara, M.D. (1) · Catherine C Coombs, MD (1) · Florian Simon (1) · Inhye Ahn, M.D. (1)
PMID 21684344, PMID 22133778, PMID 23524640, PMID 24659631, PMID 24699307, PMID 25555420, PMID 26337493, PMID 26430171, PMID 26982511, PMID 27503501, PMID 28049639, PMID 29483101, PMID 33963002, PMID 34865212, PMID 36442911, PMID 37227160, PMID 41405491
2025 (1)